Kangtai Bio to form vaccine JV with AstraZeneca

Shenzhen Kangtai Biological Products (SZSE:300601) announced plans to form a joint venture with AstraZeneca to focus on vaccine development, production, and commercialization. The initial registered capital of the JV is projected at RMB 345 million (approximately $50 million USD), with both companies holding 50% equity. The total investment is estimated at $400 million, and the project is expected to be operational by December 31, 2030. The partnership aims to develop innovative vaccines, with AstraZeneca's respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) combination vaccine, IVX-A12, being considered for joint development. Kangtai emphasized that the agreement remains subject to further details and final approvals, and that the venture is part of its international expansion strategy.